General Information of the Drug (ID: M6APDG03961)
Name
AZD4785
Synonyms
IONIS-KRAS-2.5RX
    Click to Show/Hide
Status
Phase 1
TTD Drug ID
D0DT5H
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
GTPase KRas (KRAS)
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1)
In total 1 mechanisms lead to this potential drug response
Response Summary GTPase KRas (KRAS) is a therapeutic target for AZD4785. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of AZD4785 through regulating the expression of GTPase KRas (KRAS). [1], [2]
References
Ref 1 The UCA1/KRAS axis promotes human pancreatic ductal adenocarcinoma stem cell properties and tumor growth. Am J Cancer Res. 2019 Mar 1;9(3):496-510. eCollection 2019.
Ref 2 Clinical pipeline report, company report or official report of Boehringer Ingelheim.